Navenibart is under clinical development by Astria Therapeutics and currently in Phase II for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). According to GlobalData, Phase II drugs for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Navenibart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Navenibart overview
Navenibart (STAR-0215) is under development for the treatment of hereditary angioedema. The drug candidate acts by targeting plasma kallikrein. It is administered through subcutaneous route.
Astria Therapeutics overview
Astria Therapeutics (Astria), formerly Catabasis Pharmaceuticals, is a biopharmaceutical company that discovers and develops novel therapeutics for rare allergic and immunological diseases. The company’s lead product candidate is STAR-0215, a long-acting monoclonal antibody inhibitor of plasma kallikrein for the treatment of hereditary angioedema (HAE). Its STAR-0215, against hereditary angioedema (HAE), is a rare genetic disorder that causes unpredictable attacks of swelling in the face, limbs, abdomen and airway. The company operates in Massachusetts and Delaware. Astria is headquartered in Boston, Massachusetts, the US.
For a complete picture of Navenibart’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
